Alivus Life Sciences Intrinsic Value
Alivus Life Sciences intrinsic value. Alivus Life Sciences (ALIVUS) median intrinsic value is ₹2098.14 from 10 valuation models (range ₹375–₹2666), vs current price ₹1250.60 — +67.8% upside (Trading Below Calculated Value), margin of safety 40.4%. Compare with Alivus Life Sciences valuation methods to assess whether the stock is under or overvalued.
ALIVUS Valuation Methods Summary — DCF, Graham Number & P/E
Alivus Life Sciences intrinsic value across 10 models vs current price ₹1250.60 — upside/downside and value range per method. For current market price and key ratios, visit ALIVUS screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1080.20 | ₹864.16 - ₹1296.24 | -13.6% | EPS: ₹49.10, Sector P/E: 22x |
| Book Value Method | asset | ₹2665.60 | ₹2399.04 - ₹2932.16 | +113.1% | Book Value/Share: ₹1332.80, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2131.20 | ₹1918.08 - ₹2344.32 | +70.4% | Revenue/Share: ₹1065.60, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2501.20 | ₹2251.08 - ₹2751.32 | +100.0% | EBITDA: ₹885.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2098.14 | ₹1678.51 - ₹2517.77 | +67.8% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹375.18 | ₹337.66 - ₹412.70 | -70.0% | EPS Growth: 6.5%, Fair P/E: 5.2x |
| Growth Adjusted P/E | growth | ₹754.99 | ₹679.49 - ₹830.49 | -39.6% | Revenue Growth: 5.0%, Adj P/E: 15.4x |
| ROE Based Valuation | profitability | ₹2501.20 | ₹2251.08 - ₹2751.32 | +100.0% | ROE: 18.1%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1213.43 | ₹1092.09 - ₹1334.77 | -3.0% | EPS: ₹49.10, BVPS: ₹1332.80 |
| Dividend Yield Method | dividend | ₹375.18 | ₹337.66 - ₹412.70 | -70.0% | DPS: ₹5.00, Target Yield: 2.5% |
ALIVUS Intrinsic Value vs Market Price — All Valuation Models
Alivus Life Sciences fair value range ₹375–₹2666 vs current market price ₹1250.60 across 10 valuation models. Read ALIVUS dividend track record for the complete payout history and dividend yield track record.
ALIVUS Intrinsic Value Analysis — Undervalued or Overvalued?
Alivus Life Sciences median intrinsic value ₹2098.14, current price ₹1250.60 — Trading Below Calculated Value by 67.8%, margin of safety 40.4%.
What is the intrinsic value of ALIVUS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Alivus Life Sciences (ALIVUS) is ₹2098.14 (median value). With the current market price of ₹1250.60, this represents a +67.8% variance from our estimated fair value.
The valuation range spans from ₹375.18 to ₹2665.60, indicating ₹375.18 - ₹2665.60.
Is ALIVUS undervalued or overvalued?
Based on our multi-method analysis, Alivus Life Sciences (ALIVUS) appears to be trading below calculated value by approximately 67.8%.
ALIVUS Financial Health — Key Ratios vs Industry Benchmarks
Alivus Life Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 18.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
ALIVUS Cash Flow Quality — Operating & Free Cash Flow
Alivus Life Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹565 Cr | ₹280 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹392 Cr | ₹84 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹414 Cr | ₹356 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹306 Cr | ₹233 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹598 Cr | ₹537 Cr | Positive Free Cash Flow | 8/10 |